This site is intended for US healthcare professionals only.

References:

You are now leaving
ConstrictedByTransfusions.com

You are leaving the site to go to www.geron.com.
Click Continue to proceed or close this overlay to return to ConstrictedByTransfusions.com.

Continue
  1. Sperling AS, Gibson CJ, Ebert BL. Secondary leukemia: genetics of progression from MDS to secondary leukemia. Nat Rev Cancer. 2017;17(1):5-19.
  2. Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383:1358-1374.
  3. Platzbecker U, Kubasch AS, Homer-Bouthiette C, Prebet T. Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021;35(8):2182-2198.
  4. Nachtkamp K, Stark R, Strupp C, et al. Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016;95(6):937-944.
  5. DeZern AE. Lower risk but high risk. Hematology Am Soc Hematol Educ Program. 2021;2021(1):428-434.
  6. Woll PS, Yoshizato T, Hellström-Lindberg, e, et al. Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia. J Intern Med. 2022;292:262-277.
  7. Sangerman MA, Pomares H, Alonso E, et al. Impact of red blood cell transfusion burden status in patients with lower-risk myelodysplastic syndromes. Blood. 2019;134(suppl1):3013. https://doi.org/10.1182/blood-2019-127486
  8. Cadenas FL, del Castillo TB, Sanz G, et al; Spanish MDS Registry. Clinical and biological characterization of low risk MDS patients according to ring sideroblasts (RS): comparison between the 3 subgroups in WHO2017 Classification. Blood. 2021;138(suppl 1):2610-2612. https://doi.org/10.1182/blood-2021-152678
  9. Carraway HE, Saygin C. Therapy for lower-risk MDS. Hematology. 2020;2020(1):426-433.
  10. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
  11. Mufti GJ, McLornan DP, van de Loosdrecht AA, Germing U, Hasserjian RP. Diagnostic algorithm for lower-risk myelodysplastic syndromes. Leukemia. 2018;32:1679-1696.
  12. Kubasch AS, Fenaux P, Platzbecker U. Development of luspatercept to treat ineffective erythropoiesis. Blood Adv. 2021;5(5):1565-1575.
  13. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096-1107.
  14. Chan O, Ali NA, Sallman D, et al. Therapeutic outcomes and prognostic impact of gene mutations including TP53 and SF3B1 in patients with del(5q) myelodysplastic syndromes (MDS). Clin Lymphoma Myeloma Leuk. 2022;22(7):e467-e476.
  15. Park S, Greenberg P, Yucel A, et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1 risk myelodysplastic syndrome: a systematic literature review. Brit J Haematology. 2018;184:134-160.
  16. Data on file, Geron.
  17. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627.
  18. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndrome V.3.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed August 22, 2023.
  19. Mufti GJ, Chen TL. Changing the treatment paradigm in myelodysplastic syndromes. Cancer Control. 2008;15(suppl 4):14-28.
  20. Cogle CR, Reddy SR, Chang E, et al. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence. Leuk Res. 2017;60:123-128.
  21. Remacha A, Sanz C, Contreras E, et al. Guidelines on haemovigilance of post-transfusional iron overload. Blood Transfus. 2013;11:128-139.
  22. Cerchione C, Cerciello G, Avilia S, et al. Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease. Blood Transfus. 2018;16:32-35.
  23. De Swart L, Crouch S, Hoeks M, et al. Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2020;105(3):632-639.
  24. Germing U, Oliva EN, Hiwase D, Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. Hemasphere. 2019;3(6):1-9.
  25. Kelaidi C, Park S, Sapena R, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia. 2013;27(6):1283-1290.
  26. Harnan S, Ren S, Gomersall T, et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review andmeta-analysis. Acta Haematol. 2016;136:23-42.
  27. Shastri A, Will B, Steidl U, et al. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood. 2017;129(12):1586-1594.
  28. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122(5):4021-4034.
  29. Park S, Kelaidi C, Meunier, M, et al. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expertopinion. Ann Hematol. 2020;99:7-19.
  30. Jouzier C, Cherait A, Cony-Makhoul P, et al. Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring sideroblasts (RS): a retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM). Blood. 2020;136(suppl 1):42-43.